My Bibliography

select

Nangia-Makker P, Ahrens M, Purandare N, Aras S, Li J, Gurdziel K, Jang H, Kim S, Shekhar MP. Inter-Relationship Between Melanoma Vemurafenib Tolerance Thresholds and Metabolic Pathway Choice. Cells. 2025 Jun 18;14(12). doi: 10.3390/cells14120923. PubMed PMID: 40558548; PubMed Central PMCID: PMC12191169.

select

Nangia-Makker P, Ahrens M, Purandare N, Aras S, Li J, Gurdziel K, Jang H, Kim S, Shekhar MP. Relationship between melanoma vemurafenib tolerance thresholds and metabolic pathway choice and Wnt signaling involvement. bioRxiv. 2025 Apr 2;. doi: 10.1101/2025.03.06.641924. PubMed PMID: 40093038; PubMed Central PMCID: PMC11908245.

select

Lin Q, Gajan A, Nguyen I, Sharma S, Nangia-Makker P, Firestine S, Shekhar MP. Synthesis and Biological Evaluation of Novel Triazine Analogs as Rad6 Inhibitors. Pharm Res. 2025 Mar;42(3):511-527. doi: 10.1007/s11095-025-03838-y. Epub 2025 Feb 28. PubMed PMID: 40021546.

select

Elayoubi J, Chi J, Mahmoud AA, Alloghbi A, Assad H, Shekhar M, Simon MS. A Review of Endocrine Therapy in Early-stage Breast Cancer: The Journey From Crudeness to Precision. Am J Clin Oncol. 2023 May 1;46(5):225-230. doi: 10.1097/COC.0000000000000993. Epub 2023 Mar 1. Review. PubMed PMID: 36856249.

select

Haynes BM, Cunningham K, Shekhar MPV. RAD6 inhibition enhances paclitaxel sensitivity of triple negative breast cancer cells by aggravating mitotic spindle damage. BMC Cancer. 2022 Oct 18;22(1):1073. doi: 10.1186/s12885-022-10119-z. PubMed PMID: 36258187; PubMed Central PMCID: PMC9578210.

select

Uddin MH, Zhou JY, Pimentel J, Patrick SM, Kim S, Shekhar MP, Wu GS. Proteomic Analysis Identifies p62/SQSTM1 as a Critical Player in PARP Inhibitor Resistance. Front Oncol. 2022;12:908603. doi: 10.3389/fonc.2022.908603. eCollection 2022. PubMed PMID: 35847859; PubMed Central PMCID: PMC9277186.

select

Nangia-Makker P, Shekhar MPV, Hogan V, Balan V, Raz A. MYH9 binds to dNTPs via deoxyribose moiety and plays an important role in DNA synthesis. Oncotarget. 2022;13:534-550. doi: 10.18632/oncotarget.28219. eCollection 2022. PubMed PMID: 35309869; PubMed Central PMCID: PMC8923078.

select

Gajan A, Sarma A, Kim S, Gurdziel K, Wu GS, Shekhar MP. Analysis of Adaptive Olaparib Resistance Effects on Cisplatin Sensitivity in Triple Negative Breast Cancer Cells. Front Oncol. 2021;11:694793. doi: 10.3389/fonc.2021.694793. eCollection 2021. PubMed PMID: 34367977; PubMed Central PMCID: PMC8339968.

select

Sarma A, Gajan A, Kim S, Gurdziel K, Mao G, Nangia-Makker P, Shekhar MPV. RAD6B Loss Disrupts Expression of Melanoma Phenotype in Part by Inhibiting WNT/β-Catenin Signaling. Am J Pathol. 2021 Feb;191(2):368-384. doi: 10.1016/j.ajpath.2020.10.015. Epub 2020 Nov 9. PubMed PMID: 33181138; PubMed Central PMCID: PMC7888193.

select

Gajan A, Martin CE, Kim S, Joshi M, Michelhaugh SK, Sloma I, Mittal S, Firestine S, Shekhar MPV. Alternative Splicing of RAD6B and Not RAD6A is Selectively Increased in Melanoma: Identification and Functional Characterization. Cells. 2019 Nov 1;8(11). doi: 10.3390/cells8111375. PubMed PMID: 31683936; PubMed Central PMCID: PMC6912459.

select

Haynes B, Gajan A, Nangia-Makker P, Shekhar MP. RAD6B is a major mediator of triple negative breast cancer cisplatin resistance: Regulation of translesion synthesis/Fanconi anemia crosstalk and BRCA1 independence. Biochim Biophys Acta Mol Basis Dis. 2020 Jan 1;1866(1):165561. doi: 10.1016/j.bbadis.2019.165561. Epub 2019 Oct 19. PubMed PMID: 31639439; PubMed Central PMCID: PMC6896319.

select

Saadat N, Liu F, Haynes B, Nangia-Makker P, Bao X, Li J, Polin LA, Gupta S, Mao G, Shekhar MP. Nano-delivery of RAD6/Translesion Synthesis Inhibitor SMI#9 for Triple-negative Breast Cancer Therapy. Mol Cancer Ther. 2018 Dec;17(12):2586-2597. doi: 10.1158/1535-7163.MCT-18-0364. Epub 2018 Sep 21. PubMed PMID: 30242094; PubMed Central PMCID: PMC6279467.

select

Haynes B, Sarma A, Nangia-Makker P, Shekhar MP. Breast cancer complexity: implications of intratumoral heterogeneity in clinical management. Cancer Metastasis Rev. 2017 Sep;36(3):547-555. doi: 10.1007/s10555-017-9684-y. Review. PubMed PMID: 28752247; PubMed Central PMCID: PMC5693662.

select

Sanders MA, Haynes B, Nangia-Makker P, Polin LA, Shekhar MP. Pharmacological targeting of RAD6 enzyme-mediated translesion synthesis overcomes resistance to platinum-based drugs. J Biol Chem. 2017 Jun 23;292(25):10347-10363. doi: 10.1074/jbc.M117.792192. Epub 2017 May 10. PubMed PMID: 28490629; PubMed Central PMCID: PMC5481549.

select

Haynes B, Zhang Y, Liu F, Li J, Petit S, Kothayer H, Bao X, Westwell AD, Mao G, Shekhar MPV. Gold nanoparticle conjugated Rad6 inhibitor induces cell death in triple negative breast cancer cells by inducing mitochondrial dysfunction and PARP-1 hyperactivation: Synthesis and characterization. Nanomedicine. 2016 Apr;12(3):745-757. doi: 10.1016/j.nano.2015.10.010. Epub 2015 Nov 10. PubMed PMID: 26563438; PubMed Central PMCID: PMC4809765.

select

Haynes B, Saadat N, Myung B, Shekhar MP. Crosstalk between translesion synthesis, Fanconi anemia network, and homologous recombination repair pathways in interstrand DNA crosslink repair and development of chemoresistance. Mutat Res Rev Mutat Res. 2015 Jan-Mar;763:258-66. doi: 10.1016/j.mrrev.2014.11.005. Epub 2014 Nov 20. Review. PubMed PMID: 25795124; PubMed Central PMCID: PMC4369322.

select

Kothayer H, Morelli M, Brahemi G, Elshanawani A, Abu Kull M, El-Sabbagh O, Shekhar M, Westwell A. Optimised synthesis of diamino-triazinylmethyl benzoates as inhibitors of Rad6B ubiquitin conjugating enzyme. Tetrahedron letters. 2014 October; 55:7015-7018. doi: dx.doi.org/10.1016/j.tetlet.2014.10.122.

select

Heppner GH, Shekhar M. Tumor heterogeneity is fundamental to the tumor ecosystem. Oncology (Williston Park). 2014 Sep;28(9):780-1. PubMed PMID: 25224476.

select

Rosner K, Adsule S, Haynes B, Kirou E, Kato I, Mehregan DR, Shekhar MP. Rad6 is a Potential Early Marker of Melanoma Development. Transl Oncol. 2014 May 12;7(3):384-92. doi: 10.1016/j.tranon.2014.04.009. [Epub ahead of print] PubMed PMID: 24831578; PubMed Central PMCID: PMC4145396.

select

Rosner K, Mehregan DR, Kirou E, Abrams J, Kim S, Campbell M, Frieder J, Lawrence K, Haynes B, Shekhar MP. Melanoma Development and Progression Are Associated with Rad6 Upregulation and β -Catenin Relocation to the Cell Membrane. J Skin Cancer. 2014;2014:439205. doi: 10.1155/2014/439205. Epub 2014 May 6. PubMed PMID: 24891954; PubMed Central PMCID: PMC4033428.

select

Haagenson KK, Zhang JW, Xu Z, Shekhar MP, Wu GS. Functional analysis of MKP-1 and MKP-2 in breast cancer tamoxifen sensitivity. Oncotarget. 2014 Feb 28;5(4):1101-10. doi: 10.18632/oncotarget.1795. PubMed PMID: 24658355; PubMed Central PMCID: PMC4011587.

select

Shekhar MP. The dark side of apoptosis. In: Bonavida B, editor. Molecular mechanisms of tumor cell resistance to chemotherapy New York, NY: Springer Publishers; 2013. 245-258p.

select

Kothayer H, Elshanawani AA, Abu Kull ME, El-Sabbagh OI, Shekhar MP, Brancale A, Jones AT, Westwell AD. Design, synthesis and in vitro anticancer evaluation of 4,6-diamino-1,3,5-triazine-2-carbohydrazides and -carboxamides. Bioorg Med Chem Lett. 2013 Dec 15;23(24):6886-9. doi: 10.1016/j.bmcl.2013.09.087. Epub 2013 Oct 6. PubMed PMID: 24153206.

select

Nangia-Makker P, Raz T, Tait L, Shekhar MP, Li H, Balan V, Makker H, Fridman R, Maddipati K, Raz A. Ocimum gratissimum retards breast cancer growth and progression and is a natural inhibitor of matrix metalloproteases. Cancer Biol Ther. 2013 May;14(5):417-27. doi: 10.4161/cbt.23762. Epub 2013 Feb 4. PubMed PMID: 23380593; PubMed Central PMCID: PMC3672186.

select

Shekhar MP, Kato I, Nangia-Makker P, Tait L. Comedo-DCIS is a precursor lesion for basal-like breast carcinoma: identification of a novel p63/Her2/neu expressing subgroup. Oncotarget. 2013 Feb;4(2):231-41. doi: 10.18632/oncotarget.818. PubMed PMID: 23548208; PubMed Central PMCID: PMC3712569.

select

Sanders MA, Brahemi G, Nangia-Makker P, Balan V, Morelli M, Kothayer H, Westwell AD, Shekhar MPV. Novel inhibitors of Rad6 ubiquitin conjugating enzyme: design, synthesis, identification, and functional characterization. Mol Cancer Ther. 2013 Apr;12(4):373-83. doi: 10.1158/1535-7163.MCT-12-0793. Epub 2013 Jan 21. PubMed PMID: 23339190; PubMed Central PMCID: PMC3840907.

select

Shekhar M. Intrinsic and extrinsic mechanisms of drug resistance. In: Viktorsson K, editor. Advancements in cancer research New York: Nova Publishers; 2012. 143-162p.

select

Sanders MA, Shekhar MP. Translesion synthesis and relevance in cancer therapy. In: Kimura S, Shimuzu S, editors. DNA Repair: New Research Hauppauge, NY: Nova Science; 2012. 181-209p.

select

Haagenson KK, Tait L, Wang J, Shekhar MP, Polin L, Chen W, Wu GS. Cullin-3 protein expression levels correlate with breast cancer progression. Cancer Biol Ther. 2012 Sep;13(11):1042-6. doi: 10.4161/cbt.21046. Epub 2012 Jul 24. PubMed PMID: 22825334; PubMed Central PMCID: PMC3461811.

select

Gerard B, Sanders MA, Visscher DW, Tait L, Shekhar MP. Lysine 394 is a novel Rad6B-induced ubiquitination site on beta-catenin. Biochim Biophys Acta. 2012 Oct;1823(10):1686-96. doi: 10.1016/j.bbamcr.2012.05.032. Epub 2012 Jun 15. PubMed PMID: 22705350; PubMed Central PMCID: PMC3915360.

select

Gerard B, Tait L, Nangia-Makker P, Shekhar MP. Rad6B acts downstream of Wnt signaling to stabilize β-catenin: Implications for a novel Wnt/β-catenin target. J Mol Signal. 2011 Jul 18;6:6. doi: 10.1186/1750-2187-6-6. PubMed PMID: 21767405; PubMed Central PMCID: PMC3161051.

select

Stevens JB, Abdallah BY, Liu G, Ye CJ, Horne SD, Wang G, Savasan S, Shekhar M, Krawetz SA, Hüttemann M, Tainsky MA, Wu GS, Xie Y, Zhang K, Heng HH. Diverse system stresses: common mechanisms of chromosome fragmentation. Cell Death Dis. 2011 Jun 30;2(6):e178. doi: 10.1038/cddis.2011.60. PubMed PMID: 21716293; PubMed Central PMCID: PMC3169002.

select

Shekhar MP. Drug resistance: challenges to effective therapy. Curr Cancer Drug Targets. 2011 Jun;11(5):613-23. doi: 10.2174/156800911795655921. Review. PubMed PMID: 21486215.

select

Shekhar MP. Inherent and micro-environment mediated mechanisms of drug resistance. In: Verrite EG, editor. Drug Resistant Neoplasms Hauppauge, NY: Nova Publishers; 2009. 95-112p.

select

Khdair A, Chen D, Patil Y, Ma L, Dou QP, Shekhar MP, Panyam J. Nanoparticle-mediated combination chemotherapy and photodynamic therapy overcomes tumor drug resistance. J Control Release. 2010 Jan 25;141(2):137-44. doi: 10.1016/j.jconrel.2009.09.004. Epub 2009 Sep 11. PubMed PMID: 19751777; PubMed Central PMCID: PMC3763698.

select

Shekhar MP, Biernat LA, Pernick N, Tait L, Abrams J, Visscher DW. Utility of DNA postreplication repair protein Rad6B in neoadjuvant chemotherapy response. Med Oncol. 2010 Jun;27(2):466-73. doi: 10.1007/s12032-009-9235-7. Epub 2009 May 23. PubMed PMID: 19466589.

select

Ye CJ, Stevens JB, Liu G, Bremer SW, Jaiswal AS, Ye KJ, Lin MF, Lawrenson L, Lancaster WD, Kurkinen M, Liao JD, Gairola CG, Shekhar MP, Narayan S, Miller FR, Heng HH. Genome based cell population heterogeneity promotes tumorigenicity: the evolutionary mechanism of cancer. J Cell Physiol. 2009 May;219(2):288-300. doi: 10.1002/jcp.21663. PubMed PMID: 19115235; PubMed Central PMCID: PMC2778062.

select

Shekhar MP, Tait L, Pauley RJ, Wu GS, Santner SJ, Nangia-Makker P, Shekhar V, Nassar H, Visscher DW, Heppner GH, Miller FR. Comedo-ductal carcinoma in situ: A paradoxical role for programmed cell death. Cancer Biol Ther. 2008 Nov;7(11):1774-82. doi: 10.4161/cbt.7.11.6781. Epub 2008 Nov 12. PubMed PMID: 18787417; PubMed Central PMCID: PMC4657570.

select

Khdair A, Gerard B, Handa H, Mao G, Shekhar MP, Panyam J. Surfactant-polymer nanoparticles enhance the effectiveness of anticancer photodynamic therapy. Mol Pharm. 2008 Sep-Oct;5(5):795-807. doi: 10.1021/mp800026t. Epub 2008 Jul 23. PubMed PMID: 18646775.

select

Shekhar MP, Gerard B, Pauley RJ, Williams BO, Tait L. Rad6B is a positive regulator of beta-catenin stabilization. Cancer Res. 2008 Mar 15;68(6):1741-50. doi: 10.1158/0008-5472.CAN-07-2111. PubMed PMID: 18339854.

select

Shekhar MP. Breast cancer stem cell paradigm. In: Parsons DW, editor. Stem Cells and Cancer New York: Nova Publishers; 2007. 47-64p.

select

Chavanpatil MD, Khdair A, Gerard B, Bachmeier C, Miller DW, Shekhar MP, Panyam J. Surfactant-polymer nanoparticles overcome P-glycoprotein-mediated drug efflux. Mol Pharm. 2007 Sep-Oct;4(5):730-8. doi: 10.1021/mp070024d. Epub 2007 Aug 18. PubMed PMID: 17705442.

select

Nangia-Makker P, Tait L, Shekhar MP, Palomino E, Hogan V, Piechocki MP, Funasaka T, Raz A. Inhibition of breast tumor growth and angiogenesis by a medicinal herb: Ocimum gratissimum. Int J Cancer. 2007 Aug 15;121(4):884-94. doi: 10.1002/ijc.22733. PubMed PMID: 17437270; PubMed Central PMCID: PMC3613994.

select

Shekhar MP, Santner S, Carolin KA, Tait L. Direct involvement of breast tumor fibroblasts in the modulation of tamoxifen sensitivity. Am J Pathol. 2007 May;170(5):1546-60. doi: 10.2353/ajpath.2007.061004. PubMed PMID: 17456761; PubMed Central PMCID: PMC1854950.

select

Shekhar MP, Tait L, Gerard B. Essential role of T-cell factor/beta-catenin in regulation of Rad6B: a potential mechanism for Rad6B overexpression in breast cancer cells. Mol Cancer Res. 2006 Oct;4(10):729-45. doi: 10.1158/1541-7786.MCR-06-0136. PubMed PMID: 17050667.

select

Zhao J, Zhu K, Lubman DM, Miller FR, Shekhar MP, Gerard B, Barder TJ. Proteomic analysis of estrogen response of premalignant human breast cells using a 2-D liquid separation/mass mapping technique. Proteomics. 2006 Jul;6(13):3847-61. doi: 10.1002/pmic.200500195. PubMed PMID: 16767785.

select

Shekhar MP, Nangia-Makker P, Tait L, Miller F, Raz A. Alterations in galectin-3 expression and distribution correlate with breast cancer progression: functional analysis of galectin-3 in breast epithelial-endothelial interactions. Am J Pathol. 2004 Dec;165(6):1931-41. doi: 10.1016/S0002-9440(10)63245-2. PubMed PMID: 15579437; PubMed Central PMCID: PMC1618700.

select

Lyakhovich A, Shekhar MP. RAD6B overexpression confers chemoresistance: RAD6 expression during cell cycle and its redistribution to chromatin during DNA damage-induced response. Oncogene. 2004 Apr 15;23(17):3097-106. doi: 10.1038/sj.onc.1207449. PubMed PMID: 14981545.

select

Lyakhovich A, Shekhar MP. Supramolecular complex formation between Rad6 and proteins of the p53 pathway during DNA damage-induced response. Mol Cell Biol. 2003 Apr;23(7):2463-75. doi: 10.1128/MCB.23.7.2463-2475.2003. PubMed PMID: 12640129; PubMed Central PMCID: PMC150718.

select

Shekhar MP, Pauley R, Heppner G. Host microenvironment in breast cancer development: extracellular matrix-stromal cell contribution to neoplastic phenotype of epithelial cells in the breast. Breast Cancer Res. 2003;5(3):130-5. doi: 10.1186/bcr580. Epub 2003 Feb 20. Review. PubMed PMID: 12793893; PubMed Central PMCID: PMC164997.